Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
Status:
RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with relapsed and/or refractory pancreas cancer. Participants receive 8 weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.